Biotechnology company Aptamer Group has launched a radiopharmaceutical programme to develop new therapeutic targets. The programme, launched in collaboration with Radiopharmium, will look to develop three strategic therapeutic targets across high-value clinical indications. The targets were identified through Aptamer’s Optimer platform and will now be progressed through in vitro… Read More
Aptamer Group has launched its biomarker discovery service, offering researchers in pharmaceutical, biotechnology, and diagnostic development a new approach to identify and validate new disease markers. The service integrates Aptamer’s Optimer technology with proteomic analysis to provide an unbiased, high-throughput approach to biomarker identification. This… Read More
Aptamer Group and AstraZeneca have entered a collaboration agreement to evaluate Aptamer’s Optimer fibrotic liver delivery vehicles for the targeted delivery of small interfering RNA (siRNA). Following the encouraging results achieved to-date with Aptamer’s fibrotic liver delivery vehicles, the next phase of the research will… Read More
From humble beginnings in the founder’s basement, UK-based Aptamer Group is now supplying its Optimer binders to clients across big pharma. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley. DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did… Read More
